Clinical trial NCT02135341 - References

Botulinum Toxins, Type A — Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility

Citation(s)

•   Abrams P, Kelleher CJ, Kerr LA, Rogers RG
  Overactive bladder significantly affects quality of life. Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90. Review.
•   Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network
  . Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008 Jul;180(1):217-22. doi: 10.1016/j.juro.2008.03.028.
•   Chapple CR
  Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000 May;55(5A Suppl):33-46; discussion 50. Review.
•   Cohen BL, Barboglio P, Rodriguez D, Gousse AE
  Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn. 2009;28(3):205-8. doi: 10.1002/nau.20611.
•   Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD
  Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009 Jun;181(6):2608-15. doi: 10.1016/j.juro.2009.01.117.
•   Ghalayini IF, Al-Ghazo MA
  Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn. 2007;26(4):531-6.
•   Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, Shah PJ, Malone-Lee J
  Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005 Nov;174(5):1873-7; discussion 1877.
•   Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR, Lucas MG
  Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology. 2007 Jan;69(1):69-73.
•   Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, Van Laecke E
  The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol. 2006 Jul;176(1):328-30; discussion 330-1.
•   Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L
  Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006 Jan;97(1):96-100.
•   Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R
  Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007 Dec;100(6):1302-6.
•   Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ
  Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol. 2008 Jul;54(1):181-7. doi: 10.1016/j.eururo.2007.12.029.
•   Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P
  Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006 Mar;49(3):528-35.
•   Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J
  Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol. 2007 Mar;177(3):1011-4.
•   Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC
  Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn. 2005;24(3):231-6.
•   Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ
  Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol. 2009 May;113(5):1046-51. doi: 10.1097/AOG.0b013e3181a1f5ea.
•   Khan S, Kessler TM, Apostolidis A, Kalsi V, Panicker J, Roosen A, Gonzales G, Haslam C, Elneil S, Fowler CJ, Dasgupta P
  What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol. 2009 Apr;181(4):1773-8. doi: 10.1016/j.juro.2008.11.110.
•   Kuo HC, Liao CH, Chung SD
  Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010 Dec;58(6):919-26. doi: 10.1016/j.eururo.2010.09.007.
•   Kuo HC
  Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005 Jul;66(1):94-8.
•   Kuo HC
  Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007 Oct;178(4 Pt 1):1359-63.
•   Kuo HC
  Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 2004 May;63(5):868-72.
•   Kuo HC
  Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006 Nov;68(5):993-7; discussion 997-8.
•   Kuschel S, Werner M, Schmid DM, Faust E, Schuessler B
  Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jul;19(7):905-9. doi: 10.1007/s00192-007-0548-9.
•   Liao CH, Kuo HC
  Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013 May;189(5):1804-10. doi: 10.1016/j.juro.2012.11.089.
•   Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT
  Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection. Can J Urol. 2006 Oct;13(5):3291-5.
•   Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P
  A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005 Sep;174(3):984-9.
•   Rajkumar GN, Small DR, Mustafa AW, Conn G
  A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005 Oct;96(6):848-52.
•   Sahai A, Khan MS, Dasgupta P
  Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007 Jun;177(6):2231-6.
•   Sahai A, Sangster P, Kalsi V, Khan MS, Fowler CJ, Dasgupta P
  Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int. 2009 Mar;103(5):630-4. doi: 10.1111/j.1464-410X.2008.08076.x.
•   Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B
  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006 Jul;176(1):177-85.
•   Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Stürzebecher B, Miller K, Knispel HH
  Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol. 2005 Dec;48(6):984-90; discussion 990.
•   Schulte-Baukloh H, Weiss C, Stolze T, Stürzebecher B, Knispel HH
  Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005 Jul;66(1):82-7.
•   Werner M, Schmid DM, Schüssler B
  Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol. 2005 May;192(5):1735-40.
•   White WM, Pickens RB, Doggweiler R, Klein FA
  Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol. 2008 Dec;180(6):2522-6. doi: 10.1016/j.juro.2008.08.030.
•   Yoshimura N
  Lower urinary tract symptoms (LUTS) and bladder afferent activity. Neurourol Urodyn. 2007 Oct;26(6 Suppl):908-13. Review.

Comparative Study of Safety and Efficacy Between 100 U Suburothelial Injection and 50 U Suburothelial Plus 50 U Urethral Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility

Details for clinical trial NCT02135341